This article focuses on cutaneous hematopoietic neoplasms that are more likely to be encountered in the pediatric age-group and includes both lymphoproliferative and histiocytic disorders. The cutaneous hematologic disorders in children have a different epidemiologic profile to what is seen during adulthood. Although mycosis fungoides is the most frequent form of cutaneous lymphoma in adults, it is very rare in children. Because lymphoblastic leukemias and lymphomas are more frequent in the pediatric setting, cutaneous leukemic infiltrates are relatively common in this age-group. Similarly, histiocytic disorders are more common in children, particularly Langerhans cell histiocytosis and juvenile xanthogranuloma. Notably, the histiocytic disorders have undergone significant modifications on their nomenclature in the basis of the molecular characteristics that are present in them. A summary of the most frequent cutaneous hematopoietic disorders in children will be discussed further in this review.
O’SuojiCWelchJJPerkinsSLet al.Rare pediatric non-Hodgkin lymphomas: a report from Children’s Oncology Group Study ANHL 04B1. Pediatr Blood Cancer2016; 63(5): 794–800.
2.
KempfWKazakovDVBelousovaIEMitteldorfCKerlK. Paediatric cutaneous lymphomas: a review and comparison with adult counterparts. J Eur Acad Dermatol Venereol2015; 29(9): 1696–1709.
3.
Fink-PuchesRChottAArdigoMet al.The spectrum of cutaneous lymphomas in patients less than 20 years of age. Pediatr Dermatol2004; 21(5): 525–533.
BeljaardsRCKaudewitzPBertiEet al.Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Multicenter Study of 47 patients. Cancer1993; 71(6): 2097–2104.
6.
RalfkiaerEWillemzeRPaulliMKadinME. CD30-positive T-cell Lymphoproliferative Disorders, 4th ed. Lyon, France: International Agency for Research on Cancer, 2008.
7.
WillemzeRBeljaardsRC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol1993; 28(6): 973–980.
8.
KempfW. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol2006; 33(Suppl 1): 58–70.
9.
KumarSPittalugaSRaffeldMGuerreraMSeibelNLJaffeES. Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. Pediatr Dev Pathol2005; 8(1): 52–60.
10.
PapalasJAVan MaterDWangE. Pyogenic variant of primary cutaneous anaplastic large-cell lymphoma: a lymphoproliferative disorder with a predilection for the immunocompromized and the young. Am J Dermatopathol2010; 32(8): 821–827.
11.
SciallisAPLawMEInwardsDJet al.Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders. Mod Pathol2012; 25(7): 983–992.
12.
TomaszewskiMMMoadJCLuptonGP. Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhood. J Am Acad Dermatol1999; 40(5 Pt 2): 857–861.
13.
VaidRCohenB. Primary cutaneous CD30 positive anaplastic large cell lymphoma in an adolescent. Pediatr Dermatol2009; 26(6): 721–724.
14.
MahajanVKJindalR. Primary cutaneous anaplastic large cell lymphoma in a child simulating primary cutaneous Hodgkin’s disease. Indian J Dermatol Venereol Leprol2016; 82(1): 98–101.
15.
JhalaDNMedeirosLJLopez-TerradaDJhalaNCKrishnanBShahabI. Neutrophil-rich anaplastic large cell lymphoma of T-cell lineage. A report of two cases arising in HIV-positive patients. Am J Clin Pathol2000; 114(3): 478–482.
16.
SalamaS. Primary “cutaneous” T-cell anaplastic large cell lymphoma, CD30+, neutrophil-rich variant with subcutaneous panniculitic lesions, in a post-renal transplant patient: report of unusual case and literature review. Am J Dermatopathol2005; 27(3): 217–223.
17.
KongYYDaiBKongJCLuHFShiDR. Neutrophil/eosinophil-rich type of primary cutaneous anaplastic large cell lymphoma: a clinicopathological, immunophenotypic and molecular study of nine cases. Histopathology2009; 55(2): 189–196.
18.
CamisaCHelmTNSextonCTuthillR. Ki-1-positive anaplastic large-cell lymphoma can mimic benign dermatoses. J Am Acad Dermatol1993; 29(5 Pt 1): 696–700.
19.
de BruinPCBeljaardsRCvan HeerdePet al.Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology1993; 23(2): 127–135.
20.
PlazaJAFeldmanALMagroC. Cutaneous CD30-positive lymphoproliferative disorders with CD8 expression: a clinicopathologic study of 21 cases. J Cutan Pathol2013; 40(2): 236–247.
21.
WangXBoddickerRLDasariSet al.Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. Hum Pathol2017; 64: 19–27.
22.
OnaindiaAMontes-MorenoSRodriguez-PinillaSMet al.Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features. Histopathology2015; 66(6): 846–855.
23.
SwerdlowSHCampoEPileriSAet al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood2016; 127(20): 2375–2390.
24.
BurgGKempfWCozzioAet al.WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol2005; 32(10): 647–674.
25.
WillemzeRJaffeESBurgGet al.WHO-EORTC classification for cutaneous lymphomas. Blood2005; 105(10): 3768–3785.
26.
CastanoEGlickSWolgastLet al.Hypopigmented mycosis fungoides in childhood and adolescence: a long-term retrospective study. J Cutan Pathol2013; 40(11): 924–934.
27.
CrowleyJJNikkoAVargheseAHoppeRTKimYH. Mycosis fungoides in young patients: clinical characteristics and outcome. J Am Acad Dermatol1998; 38(5 Pt 1): 696–701.
28.
El-Shabrawi-CaelenLCerroniLMedeirosLJMcCalmontTH. Hypopigmented mycosis fungoides: frequent expression of a CD8+ T-cell phenotype. Am J Surg Pathol2002; 26(4): 450–457.
29.
PopeEWeitzmanSNganBet al.Mycosis fungoides in the pediatric population: report from an international Childhood Registry of Cutaneous Lymphoma. J Cutan Med Surg2010; 14(1): 1–6.
30.
CerviniABTorres-HuamaniANSanchez-La-RosaCet al.Mycosis fungoides: experience in a pediatric hospital. Actas Dermosifiliogr2017; 108(6): 564–570.
31.
KochSEZackheimHSWilliamsMLFletcherVLeBoitPE. Mycosis fungoides beginning in childhood and adolescence. J Am Acad Dermatol1987; 17(4): 563–570.
32.
PetersMSThibodeauSNWhiteJWJrWinkelmannRK. Mycosis fungoides in children and adolescents. J Am Acad Dermatol1990; 22(6 Pt 1): 1011–1018.
33.
WainEMOrchardGEWhittakerSJSpittleMSMFRussell-JonesR. Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study. Cancer2003; 98(10): 2282–2290.
34.
ZackheimHSMcCalmontTHDeanovicFWOdomRB. Mycosis fungoides with onset before 20 years of age. J Am Acad Dermatol1997; 36(4): 557–562.
35.
TanETayYKGiamYC. Profile and outcome of childhood mycosis fungoides in Singapore. Pediatr Dermatol2000; 17(5): 352–356.
36.
WernerBBrownSAckermanAB. “Hypopigmented mycosis fungoides” is not always mycosis fungoides!. Am J Dermatopathol2005; 27(1): 56–67.
ZackheimHSMcCalmontTH. Mycosis fungoides: the great imitator. J Am Acad Dermatol2002; 47(6): 914–918.
39.
HengYKKohMJGiamYCTangMBChongWSTanSH. Pediatric mycosis fungoides in Singapore: a series of 46 children. Pediatr Dermatol2014; 31(4): 477–482.
40.
AminABurkhartCGrobenPMorrellDS. Primary cutaneous T-cell lymphoma following organ transplantation in a 16-year-old boy. Pediatr Dermatol2009; 26(1): 112–113.
41.
HodakEAmitay-LaishIFeinmesserMet al.Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement. J Am Acad Dermatol2014; 70(6): 993–1001.
42.
AlikhanAGriffinJNguyenNDavisDMGibsonLE. Pediatric follicular mucinosis: presentation, histopathology, molecular genetics, treatment, and outcomes over an 11-year period at the Mayo Clinic. Pediatr Dermatol2013; 30(2): 192–198.
43.
Hess SchmidMDummerRKempfWHiltyNBurgG. Mycosis fungoides with mucinosis follicularis in childhood. Dermatology1999; 198(3): 284–287.
44.
Santos-BrizACanuetoJGarcia-DoradoJAlonsoMTBalanzateguiAGonzalez-DiazM. Pediatric primary follicular mucinosis: further evidence of its relationship with mycosis fungoides. Pediatr Dermatol2013; 30(6): e218–220.
45.
van DoornRSchefferEWillemzeR. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol2002; 138(2): 191–198.
HelmKFCerioRWinkelmannRK. Granulomatous slack skin: a clinicopathological and immunohistochemical study of three cases. Br J Dermatol1992; 126(2): 142–147.
48.
LeBoitPEBecksteadJHBondBEpsteinWLFriedenIJParslowTG. Granulomatous slack skin: clonal rearrangement of the T-cell receptor beta gene is evidence for the lymphoproliferative nature of a cutaneous elastolytic disorder. J Invest Dermatol1987; 89(2): 183–186.
49.
NotoGPravataGMiceliSAricoM. Granulomatous slack skin: report of a case associated with Hodgkin’s disease and a review of the literature. Br J Dermatol1994; 131(2): 275–279.
50.
WieserIWohlmuthCDuvicM. Granulomatous Mycosis fungoides in an adolescent—a rare encounter and review of the literature. Pediatr Dermatol2016; 33(5): e296–e298.
51.
CamachoFMBurgGMorenoJCCamporaRGVillarJL. Granulomatous slack skin in childhood. Pediatr Dermatol1997; 14(3): 204–208.
52.
MatsuzakiYKimuraKNakanoHHanadaKSawamuraD. Localized pagetoid reticulosis (Woringer-Kolopp disease) in early childhood. J Am Acad Dermatol2009; 61(1): 120–123.
53.
MendeseGWBeckfordAKrejciNMahalingamMGoldbergLGilchrestBA. Pagetoid reticulosis in a prepubescent boy successfully treated with photodynamic therapy. Clin Exp Dermatol2012; 37(7): 759–761.
54.
MiedlerJDKristjanssonAKGouldJTamburroJGilliamAC. Pagetoid reticulosis in a 5-year-old boy. J Am Acad Dermatol2008; 58(4): 679–681.
55.
AiWZKeeganTHPressDJet al.Outcomes after diagnosis of mycosis fungoides and Sezary syndrome before 30 years of age: a population-based study. JAMA Dermatol2014; 150(7): 709–715.
56.
LeBoitPEAbelEAClearyMLet al.Clonal rearrangement of the T cell receptor beta gene in the circulating lymphocytes of erythrodermic follicular mucinosis. Blood1988; 71(5): 1329–1333.
57.
MeisterLDuarteAMDavisJPerezJLSchachnerLA. Sezary syndrome in an 11-year-old girl. J Am Acad Dermatol1993; 28(1): 93–95.
58.
MagroCMNguyenGH. Keratoderma-like T cell dyscrasia: a report of 13 cases and its distinction from mycosis fungoides palmaris et plantaris. Indian J Dermatol Venereol Leprol2016; 82(4): 395–403.
59.
SmollerBRSantucciMWoodGSWhittakerSJ. Histopathology and genetics of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am2003; 17(6): 1277–1311.
60.
RomeroMHaneyMDesantisEZlotoffB. Mycosis fungoides with focal CD 30 transformation in an adolescent. Pediatr Dermatol2008; 25(5): 565–568.
61.
CarrieEBuzynAFraitagSHermineOBodemerC. Transformed juvenile-onset mycosis fungoides: treatment by bone marrow transplantation with graft-versus-lymphoma effect. Ann Dermatol Venereol2007; 134(5 Pt 1): 471–476.
62.
GeramiPGuitartJ. The spectrum of histopathologic and immunohistochemical findings in folliculotropic mycosis fungoides. Am J Surg Pathol2007; 31(9): 1430–1438.
63.
Ben-AmitaiDMichaelDFeinmesserMHodakE. Juvenile mycosis fungoides diagnosed before 18 years of age. Acta Derm Venereol2003; 83(6): 451–456.
LuDPatelKADuvicMJonesD. Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas. J Cutan Pathol2002; 29(8): 465–472.
66.
MoonHRLeeWJWonCHet al.Paediatric cutaneous lymphoma in Korea: a retrospective study at a single institution. J Eur Acad Dermatol Venereol2014; 8(12): 1798–804.
67.
NeuhausIMRamos-CaroFAHassaneinAM. Hypopigmented mycosis fungoides in childhood and adolescence. Pediatr Dermatol2000; 17(5): 403–406.
68.
QuaglinoPZaccagnaAVerroneADardanoFBernengoMG. Mycosis fungoides in patients under 20 years of age: report of 7 cases, review of the literature and study of the clinical course. Dermatology1999; 199(1): 8–14.
69.
WangTLiuYHZhengHYet al.Hypopigmented mycosis fungoides in children: a clinicopathological study of 6 cases. Zhonghua Yi Xue Za Zhi2010; 90(46): 3287–3290.
70.
WhittamLRCalonjeEOrchardGFraser-AndrewsEAWoolfordARussell-JonesR. CD8-positive juvenile onset mycosis fungoides: an immunohistochemical and genotypic analysis of six cases. Br J Dermatol2000; 143(6): 1199–1204.
71.
SinghZNTretiakovaMSSheaCRPetronic-RosicVM. Decreased CD117 expression in hypopigmented mycosis fungoides correlates with hypomelanosis: lessons learned from vitiligo. Mod Pathol2006; 19(9): 1255–1260.
72.
HodakEDavidMMaronLAviramAKaganovskyEFeinmesserM. CD4/CD8 double-negative epidermotropic cutaneous T-cell lymphoma: an immunohistochemical variant of mycosis fungoides. J Am Acad Dermatol2006; 55(2): 276–284.
73.
WainEMOrchardGEMayouSAthertonDJMischKJRussell-JonesR. Mycosis fungoides with a CD56+ immunophenotype. J Am Acad Dermatol2005; 53(1): 158–163.
74.
PimpinelliNOlsenEASantucciMet al.Defining early mycosis fungoides. J Am Acad Dermatol2005; 53(6): 1053–1063.
75.
RamsayBDahlMCMalcolmAJWilson-JonesE. Acral pseudolymphomatous angiokeratoma of children. Arch Dermatol1990; 126(11): 1524–1525.
NijstenTCuriel-LewandrowskiCKadinME. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Arch Dermatol2004; 140(3): 306–312.
78.
KunishigeJHMcDonaldHAlvarezGJohnsonMPrietoVDuvicM. Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. Clin Exp Dermatol2009; 34(5): 576–581.
79.
ZackheimHSJonesCLeboitPEKashani-SabetMMcCalmontTHZehnderJ. Lymphomatoid papulosis associated with mycosis fungoides: a study of 21 patients including analyses for clonality. J Am Acad Dermatol2003; 49(4): 620–623.
80.
MiquelJFraitagSHamel-TeillacDet al.Lymphomatoid papulosis in children: a series of 25 cases. Br J Dermatol2014; 171(5): 1138–1146.
81.
Martorell-CalatayudAHernandez-MartinAColmeneroIet al.Lymphomatoid papulosis in children: report of 9 cases and review of the literature. Actas Dermosifiliogr2010; 101(8): 693–701.
82.
WieserIWohlmuthCNunezCADuvicM. Lymphomatoid papulosis in children and adolescents: a systematic review. Am J Clin Dermatol2016; 17(4): 319–327.
83.
BekkenkMWGeelenFAvan Voorst VaderPCet al.Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood2000; 95(12): 3653–3661.
84.
de SouzaACamilleriMJWadaDAAppertDLGibsonLEel-AzharyRA. Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients. J Am Acad Dermatol2009; 61(6): 993–1000.
85.
ScarisbrickJJEvansAVWoolfordAJBlackMMRussell-JonesR. Regional lymphomatoid papulosis: a report of four cases. Br J Dermatol1999; 141(6): 1125–1128.
86.
ThomasGJConejo-MirJSRuizAPLinares BarriosMNavarreteM. Lymphomatoid papulosis in childhood with exclusive acral involvement. Pediatr Dermatol1998; 15(2): 146–147.
87.
SagginiAGuliaAArgenyiZet al.A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol2010; 34(8): 1168–1175.
88.
KempfWKazakovDVScharerLet al.Angioinvasive lymphomatoid papulosis: a new variant simulating aggressive lymphomas. Am J Surg Pathol2013; 37(1): 1–13.
89.
PierardGE. A reappraisal of lymphomatoid papulosis and of its follicular variant. Am J Dermatopathol1981; 3(2): 179–181.
90.
PierardGEAckermanABLapiereCM. Follicular lymphomatoid papulosis. Am J Dermatopathol1980; 2(2): 173–180.
91.
KempfWKazakovDVBaumgartnerHPKutznerH. Follicular lymphomatoid papulosis revisited: a study of 11 cases, with new histopathological findings. J Am Acad Dermatol2013; 68(5): 809–816.
92.
RossNATruongHKellerMSMulhollandJKLeeJBSahuJ. Follicular lymphomatoid papulosis: an eosinophilic-rich follicular subtype masquerading as folliculitis clinically and histologically. Am J Dermatopathol2016; 38(1): e1–e10.
93.
KummerJAVermeerMHDukersDMeijerCJWillemzeR. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol1997; 109(5): 636–640.
94.
KadinME. Common activated helper-T-cell origin for lymphomatoid papulosis, mycosis fungoides, and some types of Hodgkin’s disease. Lancet1985; 2(8460): 864–865.
KaraiLJKadinMEHsiEDet al.Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol2013; 37(8): 1173–1181.
97.
BenharrochDMeguerian-BedoyanZLamantLet al.ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood1998; 91(6): 2076–2084.
98.
CriscioneVDWeinstockMA. Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002. Arch Dermatol2007; 143(7): 854–859.
99.
DelsolGFaliniBMuller-HermelinkHKet al.Anaplastic Large Cell Lymphoma (ALCL), ALK-positive, 4th ed. Lyon, France: International Agency for Research on Cancer, 2008.
100.
FaliniBPileriSZinzaniPLet al.ALK+ lymphoma: clinico-pathological findings and outcome. Blood1999; 93(8): 2697–2706.
JaffeESNicolaeAPittalugaS. Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls. Mod Pathol2013; 26(Suppl 1): S71–87.
103.
KinneyMCHigginsRAMedinaEA. Anaplastic large cell lymphoma: twenty-five years of discovery. Arch Pathol Lab Med2011; 135(1): 19–43.
104.
OschliesILisfeldJLamantLet al.ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. Haematologica2013; 98(1): 50–56.
105.
VassalloJLamantLBrugieresLet al.ALK-positive anaplastic large cell lymphoma mimicking nodular sclerosis Hodgkin’s lymphoma: report of 10 cases. Am J Surg Pathol2006; 30(2): 223–229.
106.
LamantLPileriSSabattiniEBrugieresLJaffeESDelsolG. Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in five cases. Haematologica2010; 95(3): 449–455.
107.
Beylot-BarryMGroppiAVergierBPulfordKMerlioJP. Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations. Blood1998; 91(12): 4668–4676.
108.
ChanDVSummersPTuttleMet al.Anaplastic lymphoma kinase expression in a recurrent primary cutaneous anaplastic large cell lymphoma with eventual systemic involvement. J Am Acad Dermatol2011; 65(3): 671–673.
109.
KadinMEPinkusJLPinkusGSet al.Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. Am J Surg Pathol2008; 32(9): 1421–1426.
110.
Alberti-ViolettiSTorres-CabalaCATalpurRet al.Clinicopathological and molecular study of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma. J Cutan Pathol2016; 43(12): 1121–1130.
111.
BaumCLLinkBKNeppalliVTSwickBLLiuV. Reappraisal of the provisional entity primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma: a series of 10 adult and pediatric patients and review of the literature. J Am Acad Dermatol2011; 65(4): 739–748.
112.
Garcia-HerreraAColomoLCamosMet al.Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome. J Clin Oncol2008; 26(20): 3364–3371.
113.
GroggKLJungSEricksonLAMcClureRFDoganA. Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior. Mod Pathol2008; 21(6): 708–715.
114.
BeltraminelliHLeinweberBKerlHCerroniL. Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. Am J Dermatopathol2009; 31(4): 317–322.
115.
VolksNOschliesICarioGWeichenthalMFolster-HolstR. Primary cutaneous CD4+ small to medium-size pleomorphic T-cell lymphoma in a 12-year-old girl. Pediatr Dermatol2013; 30(5): 595–599.
116.
BertiETomasiniDVermeerMHMeijerCJAlessiEWillemzeR. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol1999; 155(2): 483–492.
GuitartJMartinez-EscalaMESubtilAet al.Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. Mod Pathol2017; 30(5): 761–772.
119.
Garcia-HerreraASongJYChuangSSet al.Nonhepatosplenic gammadelta T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation. Am J Surg Pathol2011; 35(8): 1214–1225.
120.
GuitartJWeisenburgerDDSubtilAet al.Cutaneous gammadelta T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol2012; 36(11): 1656–1665.
121.
MagroCMWangX. Indolent primary cutaneous gamma/delta T-cell lymphoma localized to the subcutaneous panniculus and its association with atypical lymphocytic lobular panniculitis. Am J Clin Pathol2012; 138(1): 50–56.
MarzanoAVBertiEPaulliMCaputoR. Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases. Arch Dermatol2000; 136(7): 889–896.
124.
KerboutMMekouarFBahadiNet al.A rare pediatric case of cutaneous gamma/delta T-cell lymphoma. Ann Biol Clin (Paris)2014; 72(4): 483–485.
125.
MerrillEDAgbayRMirandaRNet al.Primary cutaneous T-cell lymphomas showing gamma-delta (gammadelta) phenotype and predominantly epidermotropic pattern are clinicopathologically distinct from classic primary cutaneous gammadelta T-cell lymphomas. Am J Surg Pathol2017; 41(2): 204–215.
126.
ParveenZThompsonK. Subcutaneous panniculitis-like T-cell lymphoma: redefinition of diagnostic criteria in the recent World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas. Arch Pathol Lab Med2009; 133(2): 303–308.
127.
HuppmannARXiLRaffeldMPittalugaSJaffeES. Subcutaneous panniculitis-like T-cell lymphoma in the pediatric age group: a lymphoma of low malignant potential. Pediatr Blood Cancer2013; 60(7): 1165–1170.
128.
KawachiYFurutaJFujisawaYNakamuraYIshiiYOtsukaF. Indolent subcutaneous panniculitis-like T cell lymphoma in a 1-year-old child. Pediatr Dermatol2012; 29(3): 374–377.
129.
WillemzeRJansenPMCerroniLet al.Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood2008; 111(2): 838–845.
130.
GuptaVAravaSBakhshiSVashishtKRReddyRGuptaS. Subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome in a child. Pediatr Dermatol2016; 33(2): e72–e76.
131.
JohnstonEELeBlancREKimJet al.Subcutaneous panniculitis-like T-cell lymphoma: pediatric case series demonstrating heterogeneous presentation and option for watchful waiting. Pediatr Blood Cancer2015; 62(11): 2025–2028.
132.
MellgrenKAttarbaschiAAblaOet al.Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases. Ann Hematol2016; 95(8): 1295–1305.
133.
KohMJSadaranganiSPChanYCet al.Aggressive subcutaneous panniculitis-like T-cell lymphoma with hemophagocytosis in two children (subcutaneous panniculitis-like T-cell lymphoma). J Am Acad Dermatol2009; 61(5): 875–881.
134.
GauJPYangCFLiuJHYuYBTzengCHChenPM. Subcutaneous panniculitis-like T cell lymphoma: familial aggregation while different response to chemotherapy. Int J Hematol2009; 89(1): 63–65.
135.
AcreeSCTovarJPPattengalePKet al.Subcutaneous panniculitis-like T-cell lymphoma in two pediatric patients: an HIV-positive adolescent and a 4-month-old infant. Fetal Pediatr Pathol2013; 32(3): 175–183.
136.
AliSKOthmanNMTagoeABTulbaAA. Subcutaneous panniculitic T cell lymphoma mimicking histiocytic cytophagic panniculitis in a child. Saudi Med J2000; 21(11): 1074–1077.
137.
Bader-MeunierBFraitagSJanssenCet al.Clonal cytophagic histiocytic panniculitis in children may be cured by cyclosporine A. Pediatrics2013; 132(2): e545–e549.
138.
BittencourtALVieiraMCarvalhoEGCunhaCAraujoI. Subcutaneous panniculitis-like T-cell lymphoma (SPTL) in a child with spontaneous resolution. Case Rep Oncol Med2011; 2011: 639240.
139.
GrassiSBorroniRGBrazzelliV. Panniculitis in children. G Ital Dermatol Venereol2013; 148(4): 371–385.
140.
KobayashiRYamatoKTanakaFet al.Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan. Pediatr Blood Cancer2010; 54(2): 212–215.
141.
LimGYHahnSTChungNGKimHK. Subcutaneous panniculitis-like T-cell lymphoma in a child: whole-body MRI in the initial and follow-up evaluations. Pediatr Radiol2009; 39(1): 57–61.
142.
MerrittBYCurryJLDuvicMVegaFSheehanAMCurryCV. Pediatric subcutaneous panniculitis-like T-cell lymphoma with features of hemophagocytic syndrome. Pediatr Blood Cancer2013; 60(11): 1916–1917.
143.
MixonBDrachLMonforteHBarbosaJ. Subcutaneous panniculitis-like T-cell lymphoma in a child with trisomy 21. Fetal Pediatr Pathol2010; 29(6): 380–384.
144.
MoraesAJSoaresPMZapataALLotitoAPSallumAMSilvaCA. Panniculitis in childhood and adolescence. Pediatr Int2006; 48(1): 48–53.
145.
NagaiKNakanoNIwaiTet al.Pediatric subcutaneous panniculitis-like T-cell lymphoma with favorable result by immunosuppressive therapy: a report of two cases. Pediatr Hematol Oncol2014; 31(6): 528–533.
146.
RajicLBilicEFemenicRet al.Subcutaneous panniculitis-like T-cell lymphoma in a 19 month-old boy: a case report. Coll Antropol2010; 34(2): 679–682.
147.
YimJHKimMYKimHOChoBChungNGParkYM. Subcutaneous panniculitis-like T-cell lymphoma in a 26-month-old child with a review of the literature. Pediatr Dermatol2006; 23(6): 537–540.
148.
WeingartnerJSZedekDCBurkhartCNMorrellDS. Lupus erythematosus panniculitis in children: report of three cases and review of previously reported cases. Pediatr Dermatol2012; 29(2): 169–176.
149.
StrausSE. The chronic mononucleosis syndrome. J Infect Dis1988; 157(3): 405–412.
150.
KimuraHMorishimaTKaneganeHet al.Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis2003; 187(4): 527–533.
KimuraHHoshinoYKaneganeHet al.Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood2001; 98(2): 280–286.
153.
ChoEYKimKHKimWSYooKHKooHHKoYH. The spectrum of Epstein-Barr virus-associated lymphoproliferative disease in Korea: incidence of disease entities by age groups. J Korean Med Sci2008; 23(2): 185–192.
154.
HongMKoYHYooKHet al.EBV-positive T/NK-cell lymphoproliferative disease of childhood. Korean J Pathol2013; 47(2): 137–147.
155.
OhshimaKKimuraHYoshinoTet al.Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int2008; 58(4): 209–217.
156.
OkanoMMatsumotoSOsatoTSakiyamaYThieleGMPurtiloDT. Severe chronic active Epstein-Barr virus infection syndrome. Clin Microbiol Rev1991; 4(1): 129–135.
157.
CohenJIKimuraHNakamuraSKoYHJaffeES. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8–9 September 2008. Ann Oncol2009; 20(9): 1472–1482.
158.
KimuraHHoshinoYHaraSet al.Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. J Infect Dis2005; 191(4): 531–539.
ChoJHKimHSKoYHParkCS. Epstein-Barr virus infected natural killer cell lymphoma in a patient with hypersensitivity to mosquito bite. J Infect2006; 52(6): e173–e176.
163.
ChungJSShinHJLeeEYChoGJ. Hypersensitivity to mosquito bites associated with natural killer cell-derived large granular lymphocyte lymphocytosis: a case report in Korea. Korean J Intern Med2003; 18(1): 50–52.
164.
FanPCChangHN. Hypersensitivity to mosquito bite: a case report. Gaoxiong Yi Xue Ke Xue Za Zhi1995; 11(7): 420–424.
165.
HidanoAKawakamiMYagoA. Hypersensitivity to mosquito bite and malignant histocytosis. Jpn J Exp Med1982; 52(6): 303–306.
166.
IshiharaSOkadaSWakiguchiHKurashigeTHiraiKKawa-HaK. Clonal lymphoproliferation following chronic active Epstein-Barr virus infection and hypersensitivity to mosquito bites. Am J Hematol1997; 54(4): 276–281.
167.
IshiharaSOkadaSWakiguchiHKurashigeTMorishimaTKawa-HaK. Chronic active Epstein-Barr virus infection in children in Japan. Acta Paediatr1995; 84(11): 1271–1275.
168.
OhsawaTMorimuraTHagariYet al.A case of exaggerated mosquito-bite hypersensitivity with Epstein-Barr virus-positive inflammatory cells in the bite lesion. Acta Derm Venereol2001; 81(5): 360–363.
169.
TokuraYTamuraYTakigawaMet al.Severe hypersensitivity to mosquito bites associated with natural killer cell lymphocytosis. Arch Dermatol1990; 126(3): 362–368.
170.
TsaiWCLuoSFLiawSJKuoTT. Mosquito bite allergies terminating as hemophagocytic histiocytosis: report of a case. Taiwan Yi Xue Hui Za Zhi1989; 88(6): 639–642, 629.
171.
IshiharaSYabutaRTokuraYOhshimaKTagawaS. Hypersensitivity to mosquito bites is not an allergic disease, but an Epstein-Barr virus-associated lymphoproliferative disease. Int J Hematol2000; 72(2): 223–228.
172.
AsadaHSaito-KatsuragiMNiizekiHet al.Mosquito salivary gland extracts induce EBV-infected NK cell oncogenesis via CD4 T cells in patients with hypersensitivity to mosquito bites. J Invest Dermatol2005; 125(5): 956–961.
173.
TokuraYMatsuokaHKogaCet al.Enhanced T-cell response to mosquito extracts by NK cells in hypersensitivity to mosquito bites associated with EBV infection and NK cell lymphocytosis. Cancer Sci2005; 96(8): 519–526.
174.
TokuraYIshiharaSTagawaSSeoNOhshimaKTakigawaM. Hypersensitivity to mosquito bites as the primary clinical manifestation of a juvenile type of Epstein-Barr virus-associated natural killer cell leukemia/lymphoma. J Am Acad Dermatol2001; 45(4): 569–578.
175.
GuptaGManIKemmettD. Hydroa vacciniforme: a clinical and follow-up study of 17 cases. J Am Acad Dermatol2000; 42(2 Pt 1): 208–213.
176.
IwatsukiKSatohMYamamotoTet al.Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Arch Dermatol2006; 142(5): 587–595.
177.
IwatsukiKYamamotoTTsujiK. Hypersensitivity to mosquito bites and hydroa vacciniforme. Nihon Rinsho2006; 64(Suppl 3): 657–661.
178.
Quintanilla-MartinezLKimuraHJaffeES. EBV+ T-cell Lymphoproliferative Disorders of Childhood, 4th ed. Lyon, France: International Agency for Research on Cancer, 2008.
179.
Quintanilla-MartinezLRidauraCNaglFet al.Hydroa vacciniforme-like lymphoma: a chronic EBV+ lymphoproliferative disorder with risk to develop a systemic lymphoma. Blood2013; 122(18): 3101–3110.
180.
BeltranBEMazaIMoises-AlfaroCBet al.Thalidomide for the treatment of hydroa vacciniforme-like lymphoma: report of four pediatric cases from Peru. Am J Hematol2014; 89(12): 1160–1161.
181.
LysellJWiegleb EdstromDLindeAet al.Antiviral therapy in children with hydroa vacciniforme. Acta Derm Venereol2009; 89(4): 393–397.
182.
GambichlerTAl-MuhammadiRBomsS. Immunologically mediated photodermatoses: diagnosis and treatment. Am J Clin Dermatol2009; 10(3): 169–180.
183.
BarrionuevoCAndersonVMZevallos-GiampietriEet al.Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol2002; 10(1): 7–14.
184.
BodduDGeorgeRNairSBindraMMathewLG. Hydroa vacciniforme-like lymphoma: a case report from India. J Pediatr Hematol Oncol2015; 37(4): e223–226.
185.
IwatsukiKOhtsukaMAkibaHKanekoF. Atypical hydroa vacciniforme in childhood: from a smoldering stage to Epstein-Barr virus-associated lymphoid malignancy. J Am Acad Dermatol1999; 40(2 Pt 1): 283–284.
186.
MaganaMSanguezaPGil-BeristainJet al.Angiocentric cutaneous T-cell lymphoma of childhood (hydroa-like lymphoma): a distinctive type of cutaneous T-cell lymphoma. J Am Acad Dermatol1998; 38(4): 574–579.
187.
OonoTArataJMasudaTOhtsukiY. Coexistence of hydroa vacciniforme and malignant lymphoma. Arch Dermatol1986; 122(11): 1306–1309.
188.
PlazaJASanguezaM. Hydroa vacciniforme-like lymphoma with primarily periorbital swelling: 7 cases of an atypical clinical manifestation of this rare cutaneous T-cell lymphoma. Am J Dermatopathol2015; 37(1): 20–25.
189.
Rodriguez-PinillaSMBarrionuevoCGarciaJet al.EBV-associated cutaneous NK/T-cell lymphoma: review of a series of 14 cases from peru in children and young adults. Am J Surg Pathol2010; 34(12): 1773–1782.
190.
SanguezaMPlazaJA. Hydroa vacciniforme-like cutaneous T-cell lymphoma: clinicopathologic and immunohistochemical study of 12 cases. J Am Acad Dermatol2013; 69(1): 112–119.
WuYHChenHCHsiaoPFTuMILinYCWangTY. Hydroa vacciniforme-like Epstein-Barr virus-associated monoclonal T-lymphoproliferative disorder in a child. Int J Dermatol2007; 46(10): 1081–1086.
193.
ChoKHLeeSHKimCWet al.Epstein-Barr virus-associated lymphoproliferative lesions presenting as a hydroa vacciniforme-like eruption: an analysis of six cases. Br J Dermatol2004; 151(2): 372–380.
194.
DemachiANagataHMorioTet al.Characterization of Epstein-Barr virus (EBV)-positive NK cells isolated from hydroa vacciniforme-like eruptions. Microbiol Immunol2003; 47(7): 543–552.
195.
MorizaneSSuzukiDTsujiKOonoTIwatsukiK. The role of CD4 and CD8 cytotoxic T lymphocytes in the formation of viral vesicles. Br J Dermatol2005; 153(5): 981–986.
196.
ZhangYNagataHIkeuchiTet al.Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol2003; 121(5): 805–814.
197.
ChanJKQuintanilla-MartinezLFerryJAPehSC. Extranodal NK/T-cell Lymphoma, Nasal Type, 4th ed. Lyon, France: International Agency for Research on Cancer, 2008.
LimaM. Aggressive mature natural killer cell neoplasms: from epidemiology to diagnosis. Orphanet J Rare Dis2013; 8: 95.
200.
TermuhlenAM. Natural killer/T-cell lymphomas in pediatric and adolescent patients. Clin Adv Hematol Oncol2017; 15(3): 200–209.
201.
HuangYXieJDingYZhouX. Extranodal natural killer/T-cell lymphoma in children and adolescents: a report of 17 cases in China. Am J Clin Pathol2016; 145(1): 46–54.
ChanJKSinVCWongKFet al.Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood1997; 89(12): 4501–4513.
204.
ChimCSMaSYAuWYet al.Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood2004; 103(1): 216–221.
205.
BarrionuevoCZahariaMMartinezMTet al.Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru. Appl Immunohistochem Mol Morphol2007; 15(1): 38–44.
206.
YamaguchiMSuzukiRKwongYLet al.Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci2008; 99(5): 1016–1020.
207.
HuangWTChangKCHuangGCet al.Bone marrow that is positive for Epstein-Barr virus encoded RNA-1 by in situ hybridization is related with a poor prognosis in patients with extranodal natural killer/T-cell lymphoma, nasal type. Haematologica2005; 90(8): 1063–1069.
208.
AuWYWeisenburgerDDIntragumtornchaiTet al.Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood2009; 113(17): 3931–3937.
209.
WangXMXuCG. Diagnostic value of serum levels of BamHI-W, LMP-1 and BZLF1 in NK/T-cell lymphoma. Zhonghua Xue Ye Xue Za Zhi2013; 34(1): 36–40.
210.
WangZYLiuQFWangHet al.Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood2012; 120(10): 2003–2010.
OhshimaKSuzumiyaJShimazakiKet al.Nasal T/NK cell lymphomas commonly express perforin and Fas ligand: important mediators of tissue damage. Histopathology1997; 31(5): 444–450.
214.
NagataHKonnoAKimuraNet al.Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood2001; 97(3): 708–713.
215.
KanavarosPLescsMCBriereJet al.Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood1993; 81(10): 2688–2695.
216.
Cuadra-GarciaIProulxGMWuCLet al.Sinonasal lymphoma: a clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. Am J Surg Pathol1999; 23(11): 1356–1369.
217.
HasserjianRPHarrisNL. NK-cell lymphomas and leukemias: a spectrum of tumors with variable manifestations and immunophenotype. Am J Clin Pathol2007; 127(6): 860–868.
218.
KuoTTShihLYTsangNM. Nasal NK/T cell lymphoma in Taiwan: a clinicopathologic study of 22 cases, with analysis of histologic subtypes, Epstein-Barr virus LMP-1 gene association, and treatment modalities. Int J Surg Pathol2004; 12(4): 375–387.
219.
SwerdlowSHJaffeESBroussetPet al.Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies. Am J Surg Pathol2014; 38(10): e60–e71.
220.
JhuangJYChangSTWengSFet al.Extranodal natural killer/T-cell lymphoma, nasal type in Taiwan: a relatively higher frequency of T-cell lineage and poor survival for extranasal tumors. Hum Pathol2015; 46(2): 313–321.
221.
KempfWKazakovDVBroekaertSMMetzeD. Pediatric CD8(+)CD56(+) non-poikilodermatous mycosis fungoides: case report and review of the literature. Am J Dermatopathol2014; 36(7): 598–602.
222.
PoppeHKerstanABockersMet al.Childhood mycosis fungoides with a CD8+ CD56+ cytotoxic immunophenotype. J Cutan Pathol2015; 42(4): 258–264.
223.
NicolaeAGanapathiKAPhamTHet al.EBV-negative aggressive NK-cell leukemia/lymphoma: clinical, pathologic, and genetic features. Am J Surg Pathol2017; 41(1): 67–74.
224.
Ferrandiz-PulidoCLopez-LermaISabadoCFerrerBPisaSGarcia-PatosV. Blastic plasmacytoid dendritic cell neoplasm in a child. J Am Acad Dermatol2012; 66(6): e238–e240.
225.
JegalianAGBuxbaumNPFacchettiFet al.Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica2010; 95(11): 1873–1879.
226.
IsaacsonPGChottANakamuraSet al.Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue (MALT Lymphoma), 4th ed. Lyon, France: International Agency for Research on Cancer, 2008.
227.
Taddesse-HeathLPittalugaSSorbaraLBusseyMRaffeldMJaffeES. Marginal zone B-cell lymphoma in children and young adults. Am J Surg Pathol2003; 27(4): 522–531.
228.
BrennerIRothSPuppeBWobserMRosenwaldAGeissingerE. Primary cutaneous marginal zone lymphomas with plasmacytic differentiation show frequent IgG4 expression. Mod Pathol2013; 26(12): 1568–1576.
229.
KempfWKazakovDVBuechnerSAet al.Primary cutaneous marginal zone lymphoma in children: a report of 3 cases and review of the literature. Am J Dermatopathol2014; 36(8): 661–666.
230.
SharonVMeccaPSSteinherzPGTrippettTMMyskowskiPL. Two pediatric cases of primary cutaneous B-cell lymphoma and review of the literature. Pediatr Dermatol2009; 26(1): 34–39.
231.
ParkMYJungHJParkJEKimYC. Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab. Eur J Dermatol2010; 20(4): 533–534.
232.
SroaNMagroCM. Pediatric primary cutaneous marginal zone lymphoma: in association with chronic antihistamine use. J Cutan Pathol2006; 33(Suppl 2): 1–5.
233.
ZambranoEMejia-MejiaOBifulcoCShinJReyes-MugicaM. Extranodal marginal zone B-cell lymphoma/maltoma of the lip in a child: case report and review of cutaneous lymphoid proliferations in childhood. Int J Surg Pathol2006; 14(2): 163–169.
Amitay-LaishITavallaeeMKimJet al.Paediatric primary cutaneous marginal zone B-cell lymphoma: does it differ from its adult counterpart?Br J Dermatol2017; 176(4): 1010–1020.
236.
GhataliaPPorterJWroblewskiDCarlsonJA. Primary cutaneous marginal zone lymphoma associated with juxta-articular fibrotic nodules in a teenager. J Cutan Pathol2013; 40(5): 477–484.
237.
SalamaS. Primary cutaneous B-cell lymphoma and lymphoproliferative disorders of skin: current status of pathology and classification. Am J Clin Pathol2000; 114 Suppl: S104–S128.
238.
De Souza A, Ferry JA, Burghart DR, et al. IgG4 expression in primary cutaneous marginal zone lymphoma: a multicenter study [published online ahead of print February 1, 2017]. Appl Immunohistochem Mol Morphol. doi:10.1097/PAI.0000000000000462.
239.
SwerdlowSH. Cutaneous marginal zone lymphomas. Semin Diagn Pathol2017; 34(1): 76–84.
240.
StreubelBLamprechtADierlammJet al.T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood2003; 101(6): 2335–2339.
241.
StreubelBSimonitsch-KluppIMullauerLet al.Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia2004; 18(10): 1722–1726.
242.
StreubelBVinatzerULamprechtARadererMChottA. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia2005; 19(4): 652–658.
243.
GuitartJGeramiP. Is there a cutaneous variant of marginal zone hyperplasia?Am J Dermatopathol2008; 30(5): 494–496.
244.
AttygalleADLiuHShiraliSet al.Atypical marginal zone hyperplasia of mucosa-associated lymphoid tissue: a reactive condition of childhood showing immunoglobulin lambda light-chain restriction. Blood2004; 104(10): 3343–3348.
245.
SwerdlowSHQuintanilla-MartinezLWillemzeRKinneyMC. Cutaneous B-cell lymphoproliferative disorders: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol2013; 139(4): 515–535.
246.
BoudovaLKazakovDVSimaRet al.Cutaneous lymphoid hyperplasia and other lymphoid infiltrates of the breast nipple: a retrospective clinicopathologic study of fifty-six patients. Am J Dermatopathol2005; 27(5): 375–386.
247.
MoulonguetIHadj-RabiaSGounodNBodemerCFraitagS. Tibial lymphoplasmacytic plaque: a new, illustrative case of a recently and poorly recognized benign lesion in children. Dermatology2012; 225(1): 27–30.
248.
SenffNJHoefnagelJJJansenPMet al.Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol2007; 25(12): 1581–1587.
249.
SenffNJNoordijkEMKimYHet al.European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood2008; 112(5): 1600–1609.
250.
CondarcoTSagatysEPrakashAVRezaniaDCualingH. Primary cutaneous B-cell lymphoma in a child. Fetal Pediatr Pathol2008; 27(4–5): 206–214.
251.
YoshiiYKatoTOnoKet al.Primary cutaneous follicle center lymphoma in a patient with WHIM syndrome. J Eur Acad Dermatol Venereol2016; 30(3): 529–530.
252.
GhislanzoniMGambiniDPerroneTAlessiEBertiE. Primary cutaneous follicular center cell lymphoma of the nose with maxillary sinus involvement in a pediatric patient. J Am Acad Dermatol2005; 52(5 Suppl 1): S73–S75.
253.
BergmanRKurtinPJGibsonLEHullPRKimlingerTKSchroeterAL. Clinicopathologic, immunophenotypic, and molecular characterization of primary cutaneous follicular B-cell lymphoma. Arch Dermatol2001; 137(4): 432–439.
254.
CerroniLArzbergerEPutzBet al.Primary cutaneous follicle center cell lymphoma with follicular growth pattern. Blood2000; 95(12): 3922–3928.
CerroniLKerlH. Cutaneous follicle center cell lymphoma, follicular type. Am J Dermatopathol2001; 23(4): 370–373.
257.
BertiEAlessiECaputoR. Reticulohistiocytoma of the dorsum (Crosti’s disease) and other B-cell lymphomas. Semin Diagn Pathol1991; 8(2): 82–90.
258.
BertiEAlessiECaputoRGianottiRDeliaDVezzoniP. Reticulohistiocytoma of the dorsum. J Am Acad Dermatol1988; 19(2 Pt 1): 259–272.
259.
Abdul-WahabATangSYRobsonAet al.Chromosomal anomalies in primary cutaneous follicle center cell lymphoma do not portend a poor prognosis. J Am Acad Dermatol2014; 70(6): 1010–1020.
260.
StreubelBScheucherBValencakJet al.Molecular cytogenetic evidence of t(14;18)(IGH;BCL2) in a substantial proportion of primary cutaneous follicle center lymphomas. Am J Surg Pathol2006; 30(4): 529–536.
261.
BorowitzMChanCH. B Lymphoblastic Leukaemia/Lymphoma, not Otherwise Specified, 4th ed. Lyon, France: International Agency for Research on Cancer, 2008.
262.
HungerSPMullighanCG. Acute lymphoblastic leukemia in children. N Engl J Med2015; 373(16): 1541–1552.
263.
SanderCAMedeirosLJAbruzzoLVHorakIDJaffeES. Lymphoblastic lymphoma presenting in cutaneous sites. A clinicopathologic analysis of six cases. J Am Acad Dermatol1991; 25(6 Pt 1): 1023–1031.
264.
KahwashSBQualmanSJ. Cutaneous lymphoblastic lymphoma in children: report of six cases with precursor B-cell lineage. Pediatr Dev Pathol2002; 5(1): 45–53.
265.
BoccaraOLaloum-GrynbergEJeudyGet al.Cutaneous B-cell lymphoblastic lymphoma in children: a rare diagnosis. J Am Acad Dermatol2012; 66(1): 51–57.
266.
LeeWJMoonHRWonCHet al.Precursor B- or T-lymphoblastic lymphoma presenting with cutaneous involvement: a series of 13 cases including 7 cases of cutaneous T-lymphoblastic lymphoma. J Am Acad Dermatol2014; 70(2): 318–325.
267.
AnsellLHMehtaJCotliarJ. Recurrent aleukemic leukemia cutis in a patient with pre-B-cell acute lymphoblastic leukemia. J Clin Oncol2013; 31(20): e353–e355.
268.
HsiaoCHSuIJ. Primary cutaneous pre-B lymphoblastic lymphoma immunohistologically mimics Ewing’s sarcoma/primitive neuroectodermal tumor. J Formos Med Assoc2003; 102(3): 193–197.
FrontanesAMontalvoFValcarcelM. Congenital leukemia with leukemia cutis: a case report. Bol Asoc Med P R2012; 104(1): 52–54.
271.
MuljonoAGrafNSArbuckleS. Primary cutaneous lymphoblastic lymphoma in children: series of eight cases with review of the literature. Pathology2009; 41(3): 223–228.
272.
YangCCChenYATsaiYLShihIHChenW. Neoplastic skin lesions of the scalp in children: a retrospective study of 265 cases in Taiwan. Eur J Dermatol2014; 24(1): 70–75.
273.
SavageNMJohnsonRCNatkunamY. The spectrum of lymphoblastic, nodal and extranodal T-cell lymphomas: characteristic features and diagnostic dilemmas. Hum Pathol2013; 44(4): 451–471.
274.
InhornRCAsterJCRoachSAet al.A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood1995; 85(7): 1881–1887.
KoksalYToyHTalimBUnalEAkcorenZCengizM. Merkel cell carcinoma in a child. J Pediatr Hematol Oncol2009; 31(5): 359–361.
277.
MarzbanSGeramizadehBFarzanehMR. Merkel cell carcinoma in a 17-year-old boy, report of a highly aggressive fatal case and review of the literature. Rare Tumors2011; 3(3): e34.
278.
IsaacsHJr. Cutaneous metastases in neonates: a review. Pediatr Dermatol2011; 28(2): 85–93.
279.
VanchinathanVMarinelliECKarthaRVUziebloARanchodMSundramUN. A malignant cutaneous neuroendocrine tumor with features of Merkel cell carcinoma and differentiating neuroblastoma. Am J Dermatopathol2009; 31(2): 193–196.
280.
MagroGLongoFRAngelicoGSpadolaSAmoreFFSalvatorelliL. Immunohistochemistry as potential diagnostic pitfall in the most common solid tumors of children and adolescents. Acta Histochem2015; 117(4–5): 397–414.
DeschJKSmollerBR. The spectrum of cutaneous disease in leukemias. J Cutan Pathol1993; 20(5): 407–410.
283.
KaiserlingEHornyHPGeertsMLSchmidU. Skin involvement in myelogenous leukemia: morphologic and immunophenotypic heterogeneity of skin infiltrates. Mod Pathol1994; 7(7): 771–779.
284.
Cho-VegaJHMedeirosLJPrietoVGVegaF. Leukemia cutis. Am J Clin Pathol2008; 129(1): 130–142.
285.
SuWPBuechnerSALiCY. Clinicopathologic correlations in leukemia cutis. J Am Acad Dermatol1984; 11(1): 121–128.
286.
ByrdJCEdenfieldWJShieldsDJDawsonNA. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol1995; 13(7): 1800–1816.
DaoudMSSnowJLGibsonLEDaoudS. Aleukemic monocytic leukemia cutis. Mayo Clinic Proc1996; 71(2): 166–168.
290.
Gil-MateoMPMiquelFJPirisMASanchezMMartin-AragonesG. Aleukemic “leukemia cutis” of monocytic lineage. J Am Acad Dermatol1997; 36(5 Pt 2): 837–840.
291.
HejmadiRKThompsonDShahFNareshKN. Cutaneous presentation of aleukemic monoblastic leukemia cutis—a case report and review of literature with focus on immunohistochemistry. J Cutan Pathol2008; 35(Suppl 1): 46–49.
292.
HeskelNSWhiteCRFrybergerSNeerhoutRCSprakerMHanifinJM. Aleukemic leukemia cutis: juvenile chronic granulocytic leukemia presenting with figurate cutaneous lesions. J Am Acad Dermatol1983; 9(3): 423–427.
293.
ImanakaKFujiwaraKSatohKet al.A case of aleukemic monocytic leukemia cutis treated with total body electron therapy. Radiat Med1988; 6(5): 229–231.
IliadisAKoletsaTGeorgiouEPatsatsiASotiriadisDKostopoulosI. Bilateral aleukemic myeloid sarcoma of the eyelids with indolent course. Am J Dermatopathol2016; 38(4): 312–314.
296.
JungHDKimHSParkYMKimHOLeeJY. Multiple granulocytic sarcomas in a patient with longstanding complete remission of acute myelogenous leukemia. Ann Dermatol2011; 23(Suppl 2): S270–S273.
297.
ZenginNKarsAOzisikYCanpinarHTurkerARuacanS. Aleukemic leukemia cutis in a patient with acute lymphoblastic leukemia. J Am Acad Dermatol1998; 38(4): 620–621.
298.
TomasiniCQuaglinoPNovelliMFierroMT. “Aleukemic” granulomatous leukemia cutis. Am J Dermatopathol1998; 20(4): 417–421.
KaneganeHNomuraKAbeAet al.Spontaneous regression of aleukemic leukemia cutis harboring a NPM/RARA fusion gene in an infant with cutaneous mastocytosis. Int J Hematol2009; 89(1): 86–90.
GruAACoughlinCCSchapiroMLet al.Pediatric aleukemic leukemia cutis: report of 3 cases and review of the literature. Am J Dermatopathol2015; 37(6): 477–484.
303.
NajemNZadehVBBadawiMKumarRAl-OtaibiSAl-AbdulrazzaqA. Aleukemic leukemia cutis in a child preceding T-cell acute lymphoblastic leukemia. Pediatr Dermatol2011; 28(5): 535–537.
304.
ZebischACerroniLBeham-SchmidCSillH. Therapy-related leukemia cutis: case study of an aggressive disorder. Ann Hematol2003; 82(11): 705–707.
BoggsDRWintrobeMMCartwrightGE. The acute leukemias. Analysis of 322 cases and review of the literature. Medicine (Baltimore)1962; 41: 163–225.
313.
Martinez-EscanameMZurielDTeeSIFriedIMassoneCCerroniL. Cutaneous infiltrates of acute myelogenous leukemia simulating inflammatory dermatoses. Am J Dermatopathol2013; 35(4): 419–424.
314.
CibullTLThomasABO’MalleyDPBillingsSD. Myeloid leukemia cutis: a histologic and immunohistochemical review. J Cutan Pathol2008; 35(2): 180–185.
315.
JonesDDorfmanDMBarnhillRLGranterSR. Leukemic vasculitis: a feature of leukemia cutis in some patients. Am J Clin Pathol1997; 107(6): 637–642.
316.
SeckinDSenolAGurbuzODemirkesenC. Leukemic vasculitis: an unusual manifestation of leukemia cutis. J Am Acad Dermatol2009; 61(3): 519–521.
317.
HarrisNLDemirjianZ. Plasmacytoid T-zone cell proliferation in a patient with chronic myelomonocytic leukemia. Histologic and immunohistologic characterization. Am J Surg Pathol1991; 15(1): 87–95.
318.
CroninDMGeorgeTISundramUN. An updated approach to the diagnosis of myeloid leukemia cutis. Am J Clin Pathol2009; 132(1): 101–110.
319.
Amador-OrtizCHurleyMYGhahramaniGKet al.Use of classic and novel immunohistochemical markers in the diagnosis of cutaneous myeloid sarcoma. J Cutan Pathol2011; 38(12): 945–953.
320.
XuBNaughtonDBusamKPulitzerM. ERG is a useful immunohistochemical marker to distinguish leukemia cutis from nonneoplastic leukocytic infiltrates in the skin. Am J Dermatopathol2016; 38(9): 672–677.
321.
FeuillardJJacobMCValensiFet al.Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood2002; 99(5): 1556–1563.
PetrellaTBagotMWillemzeRet al.Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol2005; 123(5): 662–675.
324.
FacchettiFJonesDPetrellaT. Blastic Plasmacytoid Dendritic Cell Neoplasm, 4th ed. Lyon, France: International Agency for Research on Cancer, 2008.
325.
ChaperotLBendrissNManchesOet al.Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood2001; 97(10): 3210–3217.
326.
ChaperotLPerrotIJacobMCet al.Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur J Immunol2004; 34(2): 418–426.
327.
DijkmanRvan DoornRSzuhaiKWillemzeRVermeerMHTensenCP. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood2007; 109(4): 1720–1727.
328.
MarafiotiTPatersonJCBallabioEet al.Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood2008; 111(7): 3778–3792.
329.
PetrellaTComeauMRMaynadieMet al.‘Agranular CD4+ CD56+ hematodermic neoplasm’ (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol2002; 26(7): 852–862.
330.
ChangSEChoiHJHuhJet al.A case of primary cutaneous CD56+, TdT+, CD4+, blastic NK-cell lymphoma in a 19-year-old woman. Am J Dermatopathol2002; 24(1): 72–75.
331.
EguarasAVLoRWVelosoJDTanVGEnriquezMLDel RosarioML. CD4+/CD56+ hematodermic neoplasm: blastic NK cell lymphoma in a 6-year-old child: report of a case and review of literature. J Pediatr Hematol Oncol2007; 29(11): 766–769.
332.
JuliaFDalleSDuruGet al.Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol2014; 38(5): 673–680.
333.
RossiJGFeliceMSBernasconiARet al.Acute leukemia of dendritic cell lineage in childhood: incidence, biological characteristics and outcome. Leuk Lymphoma2006; 47(4): 715–725.
334.
JohnsonRCKimJNatkunamYet al.Myeloid cell nuclear differentiation antigen (MNDA) expression distinguishes extramedullary presentations of myeloid leukemia from blastic plasmacytoid dendritic cell neoplasm. Am J Surg Pathol2016; 40(4): 502–509.
335.
JegalianAGFacchettiFJaffeES. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol2009; 16(6): 392–404.
MenezesJAcquadroFWisemanMet al.Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia2014; 28(4): 823–829.
338.
StenzingerAEndrisVPfarrNet al.Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm. Oncotarget2014; 5(15): 6404–6413.
339.
SapienzaMRFuligniFAgostinelliCet al.Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia2014; 28(8): 1606–1616.
340.
EmileJFAblaOFraitagSet al.Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood2016; 127(22): 2672–2681.
341.
Badalian-VeryGVergilioJAFlemingMRollinsBJ. Pathogenesis of Langerhans cell histiocytosis. Annu Rev Pathol2013; 8: 1–20.
342.
StinglGTamakiKKatzSI. Origin and function of epidermal Langerhans cells. Immunol Rev1980; 53: 149–174.
SalottiJANanduriVPearceMSParkerLLynnRWindebankKP. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child2009; 94(5): 376–380.
352.
WillisBAblinAWeinbergVZogerSWaraWMMatthayKK. Disease course and late sequelae of Langerhans’ cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol1996; 14(7): 2073–2082.
353.
MorrenMAVanden BroeckeKVangeebergenLet al.Diverse cutaneous presentations of langerhans cell histiocytosis in children: a retrospective cohort study. Pediatr Blood Cancer2016; 63(3): 486–492.
354.
NgSSKohMJTayYK. Cutaneous Langerhans cell histiocytosis: study of Asian children shows good overall prognosis. Acta Paediatr2013; 102(11): e514–518.
355.
ChuTD’AngioGJFavaraBELadischSNesbitMPritchardJ. Histiocytosis syndromes in children. Lancet1987; 2(8549): 41–42.
356.
LiebermanPHJonesCRSteinmanRMet al.Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years. Am J Surg Pathol1996; 20(5): 519–552.
357.
PileriSAGroganTMHarrisNLet al.Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology2002; 41(1): 1–29.
358.
RisdallRJDehnerLPDurayPKobrinskyNRobisonLNesbitMEJr. Histiocytosis X (Langerhans’ cell histiocytosis). Prognostic role of histopathology. Arch Pathol Lab Med1983; 107(2): 59–63.
359.
MotoiMHelbronDKaiserlingELennertK. Eosinophilic granuloma of lymph nodes—a variant of histiocytosis X. Histopathology1980; 4(6): 585–606.
360.
ValladeauJCauxCLebecqueSSaelandS. Langerin: a new lectin specific for Langerhans cells induces the formation of Birbeck granules. Pathol Biol (Paris)2001; 49(6): 454–455.
361.
ValladeauJClair-MoninotVDezutter-DambuyantCet al.Identification of mouse langerin/CD207 in Langerhans cells and some dendritic cells of lymphoid tissues. J Immunol2002; 168(2): 782–792.
362.
ValladeauJDezutter-DambuyantCSaelandS. Langerin/CD207 sheds light on formation of birbeck granules and their possible function in Langerhans cells. Immunol Res2003; 28(2): 93–107.
363.
ValladeauJRavelODezutter-DambuyantCet al.Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity2000; 12(1): 71–81.
364.
ChikwavaKJaffeR. Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders. Pediatr Dev Pathol2004; 7(6): 607–614.
365.
PicarsicJJaffeR. Nosology and pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am2015; 29(5): 799–823.
366.
MandelVDFerrariCCesinaroAMPellacaniGDel FornoC. Congenital “self-healing” Langerhans cell histiocytosis (Hashimoto-Pritzker disease): a report of two cases with the same cutaneous manifestations but different clinical course. J Dermatol2014; 41(12): 1098–1101.
YurkovichMWongALamJM. Solitary congenital self-healing Langerhans cell histiocytosis: a benign variant of Langerhans cell histiocytosis?Dermatol Online J2013; 19(1): 3.
369.
LongakerMAFriedenIJLeBoitPESherertzEF. Congenital “self-healing” Langerhans cell histiocytosis: the need for long-term follow-up. J Am Acad Dermatol1994; 31(5 Pt 2): 910–916.
370.
SatterEKHighWA. Langerhans cell histiocytosis: a review of the current recommendations of the Histiocyte Society. Pediatr Dermatol2008; 25(3): 291–295.
371.
HeritierSEmileJFBarkaouiMAet al.BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol2016; 34(25): 3023–3030.
DiamondELDurhamBHHarocheJet al.Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov2016; 6(2): 154–165.
374.
EmileJFDiamondELHelias-RodzewiczZet al.Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood2014; 124(19): 3016–3019.
375.
HarocheJCharlotteFArnaudLet al.High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood2012; 120(13): 2700–2703.
Su HH, Wu W, Guo Y, Chen HD, Shan SJ. Pediatric Erdheim-Chester disease with aggressive skin manifestations [published online ahead of print January 12, 2017]. Br J Dermatol. doi: 10.1111/bjd.15306.
378.
VallonthaielAGMridhaARGamanagattiSet al.Unusual presentation of Erdheim-Chester disease in a child with acute lymphoblastic leukemia. World J Radiol2016; 8(8): 757–763.
379.
HervierBHarocheJArnaudLet al.Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood2014; 124(7): 1119–1126.
380.
HarocheJAblaO. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease. Hematology Am Soc Hematol Educ Program2015; 2015: 571–578.
381.
Estrada-VerasJIO’BrienKJBoydLCet al.The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv2017; 1(6): 357–366.
382.
KimSLeeMShinHJLeeJSuhYL. Coexistence of intracranial Langerhans cell histiocytosis and Erdheim-Chester disease in a pediatric patient: a case report. Childs Nerv Syst2016; 32(5): 893–896.
383.
KrishnaVVJamesTEChangKTYenSS. Erdheim-Chester disease with rare radiological features in a 14-year old girl with pre-B acute lymphocytic leukemia and diabetes mellitus. J Radiol Case Rep2014; 8(8): 7–15.
384.
JohnsonWTPatelPHernandezAet al.Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation. J Cutan Pathol2016; 43(3): 270–275.
385.
ChanJKLamantLAlgarEet al.ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood2008; 112(7): 2965–2968.
386.
ChakrabortyRHamptonOAAbhyankarHet al.Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget2017; 8(28): 46065–46070.
387.
TechavichitPSosothikulDChaichanaTTeerapakpinyoCThornerPSShuangshotiS. BRAF V600E mutation in pediatric intracranial and cranial juvenile xanthogranuloma. Hum Pathol2017; 69: 118–122.
388.
DehnerLP. Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol2003; 27(5): 579–593.
389.
DehnerLP. Reawakening to the existence of juvenile xanthogranuloma. Am J Surg Pathol2005; 29(1): 119–120.
390.
JanssenDHarmsD. Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the kiel pediatric tumor registry. Am J Surg Pathol2005; 29(1): 21–28.
391.
FreyerDRKennedyRBostromBCKohutGDehnerLP. Juvenile xanthogranuloma: forms of systemic disease and their clinical implications. J Pediatr1996; 129(2): 227–237.
392.
SusonKMathewsRGoldsteinJDDehnerLP. Juvenile xanthogranuloma presenting as a testicular mass in infancy: a clinical and pathologic study of three cases. Pediatr Dev Pathol2010; 13(1): 39–45.
393.
ZelgerBBurgdorfWH. The cutaneous “histiocytoses”. Adv Dermatol2001; 17: 77–114.
394.
ZelgerBWCerioR. Xanthogranuloma is the archetype of non-Langerhans cell histiocytoses. Br J Dermatol2001; 145(2): 369–371.
395.
ZelgerBWSidoroffAOrchardGCerioR. Non-Langerhans cell histiocytoses. A new unifying concept. Am J Dermatopathol1996; 18(5): 490–504.
396.
ArachchillageDRCarrTFKerrBet al.Juvenile myelomonocytic leukemia presenting with features of neonatal hemophagocytic lymphohistiocytosis and cutaneous juvenile xanthogranulomata and successfully treated with allogeneic hemopoietic stem cell transplant. J Pediatr Hematol Oncol2010; 32(2): 152–155.
397.
BurgdorfWHZelgerB. JXG, NF1, and JMML: alphabet soup or a clinical issue?Pediatr Dermatol2004; 21(2): 174–176.
398.
FenotMStalderJFBarbarotS. Juvenile xanthogranulomas are highly prevalent but transient in young children with neurofibromatosis type 1. J Am Acad Dermatol2014; 71(2): 389–390.
399.
FerrariFMasurelAOlivier-FaivreLVabresP. Juvenile xanthogranuloma and nevus anemicus in the diagnosis of neurofibromatosis type 1. JAMA Dermatol2014; 150(1): 42–46.
400.
JansSRSchomerusEBygumA. Neurofibromatosis type 1 diagnosed in a child based on multiple juvenile xanthogranulomas and juvenile myelomonocytic leukemia. Pediatr Dermatol2015; 32(1): e29–32.
401.
Liy-WongCMohammedJCarletonAPopeEParkinPLara-CorralesI. The relationship between neurofibromatosis type 1, juvenile xanthogranuloma, and malignancy: A retrospective case-control study. J Am Acad Dermatol2017; 76(6): 1084–1087.
402.
ShinHTHarrisMBOrlowSJ. Juvenile myelomonocytic leukemia presenting with features of hemophagocytic lymphohistiocytosis in association with neurofibromatosis and juvenile xanthogranulomas. J Pediatr Hematol Oncol2004; 26(9): 591–595.
403.
MarrogiAJDehnerLPCoffinCMWickMR. Benign cutaneous histiocytic tumors in childhood and adolescence, excluding Langerhans’ cell proliferations. A clinicopathologic and immunohistochemical analysis. Am J Dermatopathol1992; 14(1): 8–18.
404.
GruAAHoracio MalufMD. Contributions of Dr. Louis “Pepper” Dehner to the art of cutaneous pathology, the first pediatric dermatopathologist. Semin Diagn Pathol2016; 33(6): 441–449.
GianottiRAlessiECaputoR. Benign cephalic histiocytosis: a distinct entity or a part of a wide spectrum of histiocytic proliferative disorders of children? A histopathological study. Am J Dermatopathol1993; 15(4): 315–319.
408.
KhooBPTayYK. Benign cephalic histiocytosis in Singapore—a review of 8 cases. Singapore Med J1999; 40(11): 697–699.
409.
Rodriguez-JuradoRDuran-McKinsterCRuiz-MaldonadoR. Benign cephalic histiocytosis progressing into juvenile xanthogranuloma: a non-Langerhans cell histiocytosis transforming under the influence of a virus?Am J Dermatopathol2000; 22(1): 70–74.
CaputoRErmacoraEGelmettiCBertiEGianniENigroA. Generalized eruptive histiocytoma in children. J Am Acad Dermatol1987; 17(3): 449–454.
413.
RepisoTRoca-MirallesMKanitakisJCastells-RodellasA. Generalized eruptive histiocytoma evolving into xanthoma disseminatum in a 4-year-old boy. Br J Dermatol1995; 132(6): 978–982.
414.
TangXShenHXuAet al.Spontaneous regression of generalized eruptive histiocytosis: possible involvement of apoptosis?Int J Dermatol2007; 46(10): 1073–1075.
415.
VermaSB. Generalized eruptive histiocytomas and juvenile eruptive xanthogranulomas in a 10-year-old boy: a potpourri of exotic terms indicating the need for unification. Int J Dermatol2012; 51(4): 445–447.
AttiaAMBakryOAMohamedEE. Xanthoma disseminatum: a progressive case with multisystem involvement. J Postgrad Med2014; 60(1): 69–71.
421.
ThaweraniHSanchezRLRosaiJDorfmanRF. The cutaneous manifestations of sinus histiocytosis with massive lymphadenopathy. Arch Dermatol1978; 114(2): 191–197.
422.
GoodmanWTBarrettTLDisorders of Langerhans cells and macrophages. In: BologniaJLJorrizzoJLSchafferJV (eds). Dermatology. Vol 2, 3rd ed. Philadelphia PA: Elsevier Saunders, 2013, pp. 1542–1544.
ChappellJABurkemperNMFraterJLHurleyMY. Cutaneous Rosai-Dorfman disease and morphea: coincidence or association?Am J Dermatopathol2009; 31(5): 487–489.
425.
FraterJLMaddoxJSObadiahJMHurleyMY. Cutaneous Rosai-Dorfman disease: comprehensive review of cases reported in the medical literature since 1990 and presentation of an illustrative case. J Cutan Med Surg2006; 10(6): 281–290.
426.
Cartin-CebaRGolbinJMYiESPrakashUBVassalloR. Intrathoracic manifestations of Rosai-Dorfman disease. Respir Med2010; 104(9): 1344–1349.
427.
GrabczynskaSATohCTFrancisNCostelloCBunkerCB. Rosai-Dorfman disease complicated by autoimmune haemolytic anaemia: case report and review of a multisystem disease with cutaneous infiltrates. Br J Dermatol2001; 145(2): 323–326.
428.
LuCIKuoTTWongWRHongHS. Clinical and histopathologic spectrum of cutaneous Rosai-Dorfman disease in Taiwan. J Am Acad Dermatol2004; 51(6): 931–939.
429.
KongYYLuHFZhuXZWangJShiDRKongJC. Cutaneous Rosai-Dorfman disease. Zhonghua Bing Li Xue Za Zhi2005; 34(3): 133–136.
430.
WangKHChenWYLiuHNHuangCCLeeWRHuCH. Cutaneous Rosai-Dorfman disease: clinicopathological profiles, spectrum and evolution of 21 lesions in six patients. The British journal of dermatology2006; 154(2): 277–286.
431.
ChuPLeBoitPE. Histologic features of cutaneous sinus histiocytosis (Rosai-Dorfman disease): study of cases both with and without systemic involvement. Journal of cutaneous pathology1992; 19(3): 201–206.
432.
KalaCAgarwalAKalaS. Extranodal manifestation of Rosai-Dorfman disease with bilateral ocular involvement. Journal of cytology / Indian Academy of Cytologists2011; 28(3): 131–133.
433.
LiuLPerryAMCaoWet al.Relationship between Rosai-Dorfman disease and IgG4-related disease: study of 32 cases. Am J Clin Pathol2013; 140(3): 395–402.
434.
MenonMPEvbuomwanMORosaiJJaffeESPittalugaS. A subset of Rosai-Dorfman disease cases show increased IgG4-positive plasma cells: another red herring or a true association with IgG4-related disease?Histopathology2014; 64(3): 455–459.
435.
WimmerDBRoJYLewisAet al.Extranodal Rosai-Dorfman disease associated with increased numbers of immunoglobulin g4 plasma cells involving the colon: case report with literature review. Arch Pathol Lab Med2013; 137(7): 999–1004.
436.
MorganNVMorrisMRCangulHet al.Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease. PLoS Genet2010; 6(2): e1000833.
437.
ZhengMBiRLiWet al.Generalized pure cutaneous Rosai-Dorfman disease: a link between inflammation and cancer not associated with mitochondrial DNA and SLC29A3 gene mutation?Discovery Med2013; 16(89): 193–200.
438.
Molho-PessachVRamotYCamilleFet al.H syndrome: the first 79 patients. J Am Acad Dermatol2014; 70(1): 80–88.
439.
TekinBAtayZErgunTet al.H syndrome: a multifaceted histiocytic disorder with hyperpigmentation and hypertrichosis. Acta Derm Venereol2015; 95(8): 1021–1023.
440.
VuralSErtopPDurmazCDet al.Skin-dominant phenotype in a patient with H syndrome: identification of a novel mutation in the SLC29A3 gene. Cytogenet Genome Res2017; 151(4): 186–190.
